Etoposide (VP-16) in the treatment of advanced adenocarcinoma of the pancreas.
Twenty-six patients with advanced adenocarcinoma of the pancreas were treated with etoposide (VP-16), 100-180 mg/m2 i.v., days 1, 2, and 3, monthly. Twenty-five had bidimensionally measurable disease and one had evaluable disease only. This regimen and dosage schedule were well tolerated, with minimal toxicity including myelosuppression; a median WBC count nadir of 3,600 cells/mm3 (range 200-2,400); and a median platelet nadir of 215,000 cells/mm3 (range 15,000-405,000). However, no patients responded and only two had stable disease for 3.5 and 4 months, respectively. At this dosage and schedule, there is no role for VP-16 in the treatment of advanced pancreatic adenocarcinoma.
Sternberg
C N
CN
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Magill
G B
GB
Cheng
E W
EW
Applewhite
A
A
Sordillo
P P
PP
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy*
D005047:Etoposide